OR51F2 is an olfactory receptor family member with emerging roles in cancer biology beyond its canonical odorant-sensing function. While OR51F2 was initially characterized as an odorant receptor with plasma membrane localization and olfactory receptor activity, recent evidence reveals disease-relevant functions in multiple malignancies. In prostate cancer, OR51F2 expression is significantly upregulated, and functional studies demonstrate that OR51F2 silencing suppresses cell proliferation and migration 1. Mechanistically, OR51F2 protein is stabilized through OGT-mediated O-GlcNAcylation, which subsequently activates the Wnt/β-catenin signaling pathway to promote cancer progression 1. Additionally, OR51F2 has been identified as a tumor-associated autoantigen in pancreatic adenocarcinoma, where circulating autoantibodies against OR51F2 contribute to diagnostic biomarker signatures for cancer detection 23. In low-grade gliomas, OR51F2 has been proposed as a potential mediator of temozolomide treatment resistance, correlating with reduced chemotherapy efficacy through mechanisms involving homologous recombination and DNA methylation 4. These findings suggest OR51F2 participates in oncogenic signaling pathways and represents a promising biomarker target for cancer diagnosis and therapeutic intervention.